Diffusion Pharmaceuticals, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2001-01-01
- Employees
- 13
- Market Cap
- -
Clinical Trials
9
Active:0
Completed:5
Trial Phases
3 Phases
Phase 1:6
Phase 2:2
Phase 3:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (9 trials with phase data)• Click on a phase to view related trials
Phase 1
6 (66.7%)Phase 2
2 (22.2%)Phase 3
1 (11.1%)Study of Trans Sodium Crocetinate in Patients With Interstitial Lung Disease
Phase 2
Terminated
- Conditions
- Interstitial Lung Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-10-15
- Last Posted Date
- 2022-08-10
- Lead Sponsor
- Diffusion Pharmaceuticals Inc
- Target Recruit Count
- 18
- Registration Number
- NCT05079126
- Locations
- 🇺🇸
Pulmonary Associates, P.A., Phoenix, Arizona, United States
Randomized, Double-Blind, Placebo-Controlled, Crossover Study of Trans Sodium Crocetinate in Healthy Volunteers Exercising at Altitude
Phase 1
Completed
- Conditions
- Healthy Volunteers With Induced Hypoxia
- Interventions
- First Posted Date
- 2021-09-08
- Last Posted Date
- 2022-04-13
- Lead Sponsor
- Diffusion Pharmaceuticals Inc
- Target Recruit Count
- 30
- Registration Number
- NCT05036980
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
Safety and Efficacy of Trans Sodium Crocetinate (TSC) in Enhancing Tissue Oxygen Levels in Healthy Volunteers
- First Posted Date
- 2021-03-22
- Last Posted Date
- 2023-07-11
- Lead Sponsor
- Diffusion Pharmaceuticals Inc
- Target Recruit Count
- 30
- Registration Number
- NCT04808622
- Locations
- 🇺🇸
Altasciences Clinical Kansas Inc, Overland Park, Kansas, United States
Safety and Efficacy of Trans Sodium Crocetinate (TSC) in SARS-CoV-2 (COVID-19) Infected Subjects
Phase 1
Completed
- Conditions
- SARS-CoV-2 (Covid19)
- Interventions
- Drug: Normal saline
- First Posted Date
- 2020-10-05
- Last Posted Date
- 2022-04-14
- Lead Sponsor
- Diffusion Pharmaceuticals Inc
- Target Recruit Count
- 25
- Registration Number
- NCT04573322
- Locations
- 🇷🇴
National Institute of Infectious Diseases- Prof. Dr. Matei Balş, Bucharest, Romania
Efficacy and Safety of Trans Sodium Crocetinate (TSC) for Treatment of Suspected Stroke
- First Posted Date
- 2018-12-04
- Last Posted Date
- 2021-06-18
- Lead Sponsor
- Diffusion Pharmaceuticals Inc
- Target Recruit Count
- 6
- Registration Number
- NCT03763929
- Locations
- 🇺🇸
University of California, Los Angeles, Los Angeles, California, United States
🇺🇸University of Virginia, Charlottesville, Virginia, United States
- Prev
- 1
- 2
- Next
News
No news found